Literature DB >> 31630733

Molecular Imaging for Radiotherapy Planning and Response Assessment for Cervical Cancer.

Alexander J Lin1, Farrokh Dehdashti2, Perry W Grigsby3.   

Abstract

Positron emission tomography (PET) with [18F]fluorodeoxyglucose (FDG) leverages imaging contrast from accelerated and aberrant glucose metabolism, which is a hallmark of cancer. FDG-PET is essential for assessing involved lymph nodes and distant metastases for cervical cancer. It is also utilized for target delineation in radiation treatment planning, with investigations into functional bone marrow sparing intensity modulated radiation therapy. Tumor heterogeneity in FDG-uptake is part of a radiomics approach to potentially escalate treatment to radiation-resistant tumors. Standardizing posttreatment PET surveillance could also allow early surgical salvage of recurrent tumors. The future of molecular imaging in cervical cancer will require development of novel PET tracers to personalize treatments based on tumor biology.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31630733     DOI: 10.1053/j.semnuclmed.2019.06.009

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  8 in total

1.  Impact of tumor histology on detection of pelvic and para-aortic nodal metastasis with 18F-fluorodeoxyglucose-positron emission tomography in stage IB cervical cancer.

Authors:  Alexander J Lin; Jason D Wright; Farrokh Dehdashti; Barry A Siegel; Stephanie Markovina; Julie Schwarz; Premal H Thaker; David G Mutch; Matthew A Powell; Perry W Grigsby
Journal:  Int J Gynecol Cancer       Date:  2019-08-30       Impact factor: 3.437

2.  Pretreatment 18F-FDG uptake heterogeneity can predict treatment outcome of carbon ion radiotherapy in patients with locally recurrent nasopharyngeal carcinoma.

Authors:  Guang Ma; Bingxin Gu; Jiyi Hu; Lin Kong; Jiangang Zhang; Zili Li; Yangbo Xue; Jiade Lu; Junning Cao; Jingyi Cheng; Yingjian Zhang; Shaoli Song; Zhongyi Yang
Journal:  Ann Nucl Med       Date:  2021-04-28       Impact factor: 2.668

Review 3.  PET-CT in Clinical Adult Oncology-IV. Gynecologic and Genitourinary Malignancies.

Authors:  Ahmed Ebada Salem; Gabriel C Fine; Matthew F Covington; Bhasker R Koppula; Richard H Wiggins; John M Hoffman; Kathryn A Morton
Journal:  Cancers (Basel)       Date:  2022-06-18       Impact factor: 6.575

4.  Long-Term Outcomes of Cervical Cancer Patients Treated With Definitive Chemoradiation Following a Complete Metabolic Response.

Authors:  A J Lin; F Dehdashti; L S Massad; P H Thaker; M A Powell; D G Mutch; J K Schwarz; S Markovina; B A Siegel; P W Grigsby
Journal:  Clin Oncol (R Coll Radiol)       Date:  2021-02-11       Impact factor: 4.126

Review 5.  Radiomics in radiation oncology for gynecological malignancies: a review of literature.

Authors:  Morgan Michalet; David Azria; Marion Tardieu; Hichem Tibermacine; Stéphanie Nougaret
Journal:  Br J Radiol       Date:  2021-05-07       Impact factor: 3.629

6.  Endostar, an Antiangiogenesis Inhibitor, Combined With Chemoradiotherapy for Locally Advanced Cervical Cancer.

Authors:  Heming Lu; Yuying Wu; Xu Liu; Huixian Huang; Hailan Jiang; Chaohua Zhu; Yuping Man; Zhaohong Chen; Xianfeng Long; Qiang Pang; Luxing Peng; Xianglong Li; Junzhao Gu; Shan Deng; Ligang Xing
Journal:  Oncol Res       Date:  2021-09-20       Impact factor: 5.574

7.  Repeatability of 18F-FDG PET Radiomic Features in Cervical Cancer.

Authors:  John P Crandall; Tyler J Fraum; MinYoung Lee; Linda Jiang; Perry Grigsby; Richard L Wahl
Journal:  J Nucl Med       Date:  2020-10-02       Impact factor: 10.057

Review 8.  Image guidance in radiation therapy for better cure of cancer.

Authors:  Vincent Grégoire; Matthias Guckenberger; Karin Haustermans; Jan J W Lagendijk; Cynthia Ménard; Richard Pötter; Ben J Slotman; Kari Tanderup; Daniela Thorwarth; Marcel van Herk; Daniel Zips
Journal:  Mol Oncol       Date:  2020-06-29       Impact factor: 6.603

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.